CurrentAetnaPolicy 0579

T-Wave Alternans

Governs use of microvolt T‑wave alternans diagnostic testing (spectral analytic method) for evaluation of persons at risk of sudden cardiac death, including coverage tied to criteria for implantable cardio‑defibrillator placement. Also lists indications considered experimental/investigational.

Policy Summary

PayerAetna

PolicyT-Wave Alternans

Policy CodePolicy 0579

Change TypeAnnual review (no material changes)

Effective DateNov 13, 2001

Next Review DateJun 13, 2024

Key ActionObtain prior authorization when billing CPT 93025 for MTWA testing intended to assess ventricular arrhythmia risk in candidates for ICD placement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

spectralcovered MTWA method

>12kstudies supporting TWA predictivity

OR 59.2post-op MTWA mortality OR

45 studiesmeta-analysis dataset

11/13/2001policy effective

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

MTWA for ICD evaluation

Covered when ALL of the following are met:

Covered indication: Microvolt T-wave alternans diagnostic testing using the spectral analytic method is medically necessary for the evaluation of persons at risk of sudden cardiac death who meet criteria for implantable cardioverter-defibrillator placement.

Direct policy statement identifying covered use.

Experimental and investigational indications

MTWA is considered experimental and investigational for the following indications (effectiveness not established):

Listed investigational indications: Includes diagnosis and risk assessment of acute coronary syndrome; diagnosis of reversible myocardial ischemia in individuals without structural heart disease; evaluation of non-pathological preterm infants; evaluation of children and adolescents with Eisenmenger syndrome; evaluation of malignant ventricular arrhythmias in Chagas disease; evaluation of the adequacy of medical therapy; guidance of anti-arrhythmic therapy; judgment of the severity of ischemic cardiomyopathy; prediction of major adverse cardiac events in ischemic heart failure; prediction of post-operative mortality in cardiac surgery; prognosis of myocardial function in newborns with hypoxic-ischemic encephalopathy; prognosis of pulmonary arterial hypertension; risk assessment of sudden cardiac death in children with chronic renal failure; risk stratification following repair of tetralogy of Fallot; risk stratification in Brugada syndrome; tracking changes in risk during cardiac disease progression; and MTWA combined with electrophysiologic study for prediction of ventricular tachyarrhythmias in arrhythmogenic right ventricular cardiomyopathy.

List is not all-inclusive as stated in policy.

Evidence summaries (no coverage rules)

Evidence summaries and prognostic findings (no explicit coverage decision in these chunks):

Meta-analysis evidence: Meta-analysis of 45 studies (6,088 patients) found modest predictive performance for multiple risk stratification tests; TWA had an odds ratio of 4.66 (95% CI: 2.55–8.53).

Publication bias reduced ORs but associations persisted.

Methodological consideration: Spectral and modified moving average (MMA) methods differ; withdrawal of beta-blockers before spectral TWA testing may lead to false-negative results; proper use of commercial software and test conditions affect predictive validity.

Operational factors influence test performance.

Population-specific findings: Studies report associations between abnormal/non-negative MTWA and outcomes in multiple populations including Chagas disease, repaired tetralogy of Fallot, Brugada syndrome, pediatric chronic renal failure, pulmonary arterial hypertension, and post-operative cardiac surgery cohorts.

Strength and applicability vary; many studies call for further research.

Evidence contexts where MTWA/TWA was studied

Reported clinical contexts and study findings where MTWA/TWA was evaluated:

Perioperative cardiac surgery risk: MTWA measured at the end of surgery was significantly associated with in-hospital mortality (univariate OR 27.378; multivariate OR 59.225) and mid-term mortality (HR 4.337); combining MTWA with EuroSCORE II improved AUC from 0.764 to 0.929.not applicable

Study limited by technical exclusions and unclear management implications.

Detection of reversible ischemia without structural heart disease: In 101 patients, standard MTWA sensitivity 59.6% and specificity 91.8% for CAD detection; modified criteria (MTWA > 1.5 µV at 115–125 bpm) yielded sensitivity 86.5% and specificity 95.9%; exercise ECG had higher sensitivity but lower specificity.MTWA > 1.5 µV at HR 115–125 bpm

Small pilot study; encourages larger trials.

ARVC prognosis with MTWA + EPS:

The policy lists specific ICD‑10 diagnosis codes that are covered when selection criteria are met and also identifies diagnoses that are not covered for indications enumerated in this Clinical Policy Bulletin. Notably, B57.0–B57.5 (Chagas' disease) is explicitly listed as an ICD‑10 code not covered for indications listed in the CPB, and therefore MTWA testing for the Chagas indications described in this document is considered not covered. The CPB also enumerates other cardiac and neonatal ICD‑10 codes that are covered only when the policy’s selection criteria are satisfied (see policy coding tables).

UpToDate reviews cited in the policy do not endorse MTWA as a standard diagnostic or management tool in certain congenital and channelopathy contexts. Specifically, UpToDate discussions of tetralogy of Fallot and of Brugada syndrome do not mention MTWA as an accepted method for risk stratification or routine clinical management, and the policy therefore treats MTWA use in these settings as investigational or not established.

Several studies reporting positive MTWA findings did not identify clear, actionable interventions for patients with abnormal results. For example, a perioperative cardiac surgery study found MTWA positivity associated with higher mortality but did not suggest specific early interventions to reduce post‑operative mortality; the authors noted that positive MTWA often reflected very ill patients (e.g., in circulatory shock) rather than a clearly modifiable arrhythmia substrate.

This Clinical Policy Bulletin is an administrative document to assist in administering plan benefits and is not a contract or a guarantee of coverage. It provides a partial, general description of plan benefits; specific coverage and exclusion decisions depend on the member’s plan and may differ from the CPB.

The policy states that microvolt T‑wave alternans (MTWA) diagnostic testing using the spectral analytic method is the method considered in the medical necessity determination. For indications outside those specified for ICD evaluation, MTWA testing (including use of the spectral analytic method) is considered experimental and investigational and therefore not medically necessary.

Major society guidance and an UpToDate review cited in the policy emphasize that specific guidance is lacking on how to use TWA in clinical practice. The review notes controversy about optimal measurement conditions and detection criteria, indicating that standardization and clinical applicability remain unresolved.

In some clinical cohorts MTWA did not independently predict major adverse cardiac events after multivariable adjustment. For example, in an ischemic heart failure cohort MTWA was associated with events on univariate analysis but did not remain an independent predictor in multivariate models, whereas baroreflex sensitivity and reduced LVEF did. Similarly, perioperative MTWA associations with mortality were reported but causality and management implications were uncertain.

Coding and Diagnostic Context

Covered CPT Codes (if selection criteria met)CPTCovered

93025

Microvolt T-wave alternans for assessment of ventricular arrhythmias

Other related CPT CodesCPT

93000-93010	Electrocardiogram
93224	External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation
93225	Recording (includes connection, recording, and disconnection)
93226	Scanning analysis with report
93278	Signal-averaged electrocardiography (SAECG), with or without ECG
93600-93662	Intracardiac electrophysiological procedures/studies

ICD-10 Codes covered if selection criteria are metICD-10Covered

I42.0-I42.2,I42.5,I42.8-I42.9	Other and unspecified cardiomyopathies
I46.2-I46.9	Cardiac arrest
I47.0-I47.9	Paroxysmal tachycardia
I49.01	Ventricular fibrillation
I49.02	Ventricular flutter
I49.2	Junctional premature depolarization
I49.3	Ventricular premature depolarization

ICD-10 Codes not covered for indications listedICD-10Not Covered

B57.0-B57.5

Chagas' disease

Additional ICD-10 codes referencedICD-10

I20.0-I25.9	Ischemic Heart Disease (including Ischemic Heart Failure)
I25.110,I25.112,I25.700,I25.702,I25.710,I25.712,I25.720,I25.722,I25.730,I25.732,I25.750,I25.752,I25.760,I25.762,I25.790,I25.792	Atherosclerotic heart disease with unstable angina pectoris (various)
I27.0	Primary pulmonary hypertension
I27.83	Eisenmenger's syndrome
I48.0-I48.1,I49.1,I49.40-I49.9	Other cardiac arrhythmias (Brugada syndrome)
N18.1-N18.9	Chronic kidney disease (CKD)
P07.00-P07.03,P07.10-P07.18,P07.20-P07.26,P07.30-P07.39	Various preterm/extremely low birth weight newborn codes
P91.60-P91.63	Hypoxic ischemic encephalopathy (HIE)
Q21.3	Tetralogy of Fallot
R00.1	Bradycardia, unspecified

1–10 of 12

1/2

LVEF context

Context of useUsed in study populations with depressed LVEF and heart failure; document notes MTWA is investigated alongside LVEF assessment but does not specify a numeric LVEF threshold in this section.

Brugada max‑TWA cutoff

Reported cutoff>= 42 µV (3L‑V2 lead, morning in summer) as the optimal ROC-derived threshold in a Brugada syndrome cohort

MTWA diagnostic threshold (modified criteria)

Modified diagnostic thresholdMTWA > 1.5 µV measured at heart rate 115–125 bpm (reported as best balance of sensitivity and specificity for detection of reversible ischemia)

Study population101 patients with suspected CAD without structural heart disease; compared to exercise ECG and coronary angiography

Performance noteModified criterion produced sensitivity 86.5% and specificity 95.9% in the study

ARVC prognostic MaxValt cutoff

Prognostic MaxValt cutoffMaxValt = 23.5 µV identified by ROC as the optimal cut‑off to predict events in ARVC patients

ContextStudy combined MaxValt with inducible VT on EPS to improve AUC for event prediction in 35 ARVC patients with preserved LV function

Effect sizeMaxValt independently predicted events (HR per µV 1.06) in multivariate analysis

Typical TWAA in non-pathological preterm infants

Observed TWAATWAA = 26 ± 11 µV in 10 non‑pathological preterm infants (heart‑rate adapting matched‑filter method)

Sample and limitationsSmall retrospective sample (n=10); correlations reported with birth weight, gestational age–birth weight ratio and HRV

InterpretationAuthors state clinical meaning uncertain and further investigation required regarding SIDS risk implications

Provider Actions, Billing and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required when billing CPT 93025 (Microvolt T‑wave alternans for assessment of ventricular arrhythmias) for MTWA testing to assess ventricular arrhythmia risk. Obtain authorization prior to performing/testing when plan benefits require it.

Affected CPT: 93025 (Microvolt T‑wave alternans)

Note

Prior Authorization — None Specified in Some Cases

No additional specific prior authorization procedure codes or step‑therapy sequencing are specified elsewhere in this policy; some plan variations may not require prior authorization. Verify member‑specific benefits and any local payer requirements.

Prior authorization — none specified in some plan documents

Prior Authorization

Prior Authorization Guidance

Prior authorization guidance: when prior authorization is required for MTWA, documentation should show clinical indication (risk stratification for sudden cardiac death or evaluation tied to ICD candidacy), use of the spectral analytic method, and that testing will influence management (e.g., ICD decision). If used for indications listed as experimental/investigational in this policy, coverage is not supported.

Document indication and how results will affect management
Specify analytic method used (spectral analytic method)

Note

Prior Authorization Note

Prior authorization note: the policy history and review dates are maintained in the policy; explicit payer prior authorization procedures and codes may be defined by the member’s plan. Check the member’s benefit plan for administrative requirements and prior authorization pathways.

Policy effective date: 2001-11-13
Next review: 06/13/2024

Note

MTWA Testing: Medically Necessary When Using Spectral Analytic Method

MTWA testing performed using the spectral analytic method is considered medically necessary for evaluation of persons at risk of sudden cardiac death who meet criteria for ICD placement.

MTWA using spectral analytic method: medically necessary for ICD candidacy risk stratification

Step Therapy

No Procedural or Prior Therapy Requirements Specified

No explicit procedural prerequisites or prior therapeutic sequencing (step therapy) are specified in this policy for MTWA testing. MTWA is positioned alongside LVEF assessment, Holter monitoring, and electrophysiologic study as a risk stratification tool.

No step therapy requirements specified
MTWA is a risk stratification option alongside LVEF, Holter, EPS

Note

Suggested Testing Sequence

Suggested testing sequence: when evaluating reversible ischemia, consider exercise ECG (exercise ECG ST‑segment testing) first where appropriate; MTWA may be considered in select contexts but is primarily used for arrhythmic risk stratification rather than routine ischemia detection.

Consider exercise ECG first for ischemia evaluation when appropriate
MTWA may detect ischemia in some studies but is not the primary standard for ischemia testing

Denial Risk

Technical/Test Quality Risks

Technical/test quality risk: technical problems, device malfunction, and high unusable‑test rates have been reported; such issues may lead to test exclusion or unusable results. Ensure equipment functioning and adequate recording quality prior to testing.

High unusable rate reported in some series due to device or technical problems
Document any test exclusions or unusable results

Documentation Required

Documentation Should Support MTWA Test Method and Clinical Indication

Documentation requirements: medical record should document the clinical indication, how the MTWA result will influence management (e.g., ICD decision), the analytic method used (spectral analytic method specified for coverage), beta‑blocker management around testing if relevant, and use of commercial systems/software when applicable.

Document indication and testing context (risk stratification, ICD candidacy)
Document analytic method used (spectral analytic)
Document beta‑blocker management and commercial system/software used

Background and Definitions

T‑wave alternans refers to a beat‑to‑beat fluctuation in the ECG T‑wave and is considered a marker of repolarization instability and electrical instability that can precede ventricular tachyarrhythmias. Microvolt T‑wave alternans (MTWA) detects very small (microvolt‑level) T‑wave voltage changes using high‑resolution electrodes and signal analysis and has been investigated as a noninvasive tool to assess risk of sudden cardiac death.

Microvolt T‑wave alternans (MTWA)

DefinitionHigh‑resolution detection of beat‑to‑beat T‑wave voltage changes at the microvolt level used to assess ventricular arrhythmia risk via spectral methods

Measurement conditionsPerformed with high‑resolution electrodes during controlled exercise and analyzed with spectral analysis software

Clinical intentInvestigated as a noninvasive risk stratification tool to identify patients at risk of sudden cardiac death

Spectral analytic method

Method descriptionA frequency‑domain signal‑processing (spectral) algorithm used to detect MTWA; CMS and the policy state coverage applies only when this method is used

Operational noteSpectral analysis calculates minute beat‑to‑beat voltage changes and produces a report for physician interpretation

Regulatory contextCMS decision memorandum recognized spectral analytic method as the evidence‑supported algorithm

Spectral MTWA vs MMA

Methods distinguishedTwo commercial methods are described: frequency‑domain spectral analysis and time‑domain modified moving average (MMA); both have been used in studies and cleared by FDA

Performance considerationsPrediction differed between methods in some prospective studies, potentially related to beta‑blocker withdrawal before spectral testing

Documentation implicationPolicy emphasizes noting which method (spectral vs MMA) was used because predictive performance and coverage depend on method

Non‑negative MTWA

Non‑negative categoryResults classified as positive or indeterminate; many studies combine positive and indeterminate into a single non‑negative (abnormal) category associated with higher arrhythmic risk

Study examplesChagas and other disease cohorts reported higher event rates with non‑negative MTWA (e.g., 81.8% non‑negative in Chagas subgroup)

ImplicationCombining positive and indeterminate increases sensitivity for identifying higher‑risk patients but may include uncertain results

MTWA definition reiteration

Restated definitionBeat‑to‑beat fluctuation in T‑wave amplitude measurable at microvolt levels, detectable by methods such as modified moving average (MMA) or spectral analysis

Clinical applicationUsed experimentally for risk stratification of ventricular tachyarrhythmias and studied across multiple patient populations

Measurement contextRequires high‑resolution electrodes, controlled exercise, and specialized software for detection and reporting

MaxValt

ConceptMaxValt denotes the maximal TWA amplitude (µV) measured in a patient and has been used as a prognostic metric in studies

Study useIn ARVC cohort MaxValt median reported as 17.0 µV with ROC‑derived optimal cut‑off 23.5 µV for event prediction

Interpretive noteMaxValt may be combined with EPS findings to improve prognostic accuracy but is study‑specific and not standardized across settings

microvolt T-wave alternans

Concise definitionMicrovolt T‑wave alternans: beat‑to‑beat variability in the ECG T‑wave amplitude at the microvolt level used for ventricular arrhythmia risk stratification

Measurement methodsDetected using spectral analysis or time‑domain algorithms (MMA) and requiring high‑resolution electrodes and specialized software

Reference supportConsensus guidelines and FDA 510(k) clearance for commercial systems are cited in the policy references

OpenPayer

T-Wave Alternans

Coverage Criteria for MTWA Testing

Coding and Diagnostic Context

Provider Actions, Billing and Documentation

Background and Definitions

Policy Revision History